NCEL
NewcelX Ltd. (NASDAQ)
Healthcare — Biotechnology
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Price History
Fundamentals
| Market Cap | $20.73M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-2.16 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 4.90 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 81.7 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $28.03 |
| 52-Week Low | $1.83 |
| 50-Day Avg | $3.46 |
| 200-Day Avg | $5.58 |
| Avg Volume | 52.4K |
| Volume | 5.6K |
Performance Analysis
NEUTRALNCEL presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report